My Locations
About Me
I specialize in the treatment of gastrointestinal (GI) cancers with a focus on clinical trials. Clinical trial patients can come to me at any point during their disease, but they usually come to me looking for an alternative therapy once standard treatments have not been effective. I decided to become a doctor later in my career. I originally graduated from university with a non-science degree, but the excitement of advancing medical breakthroughs inspired me to start a career in medicine. As a Duke physician, I enjoy the diverse experiences that I get to have each week. In addition to taking care of patients and conducting research, I work closely with other doctors on crafting treatment plans. I also find it fulfilling to be able to apply my research to patient care. In my spare time, I enjoy spending time with my family, jogging and skiing.
- Professor of Medicine, Medicine, Medical Oncology 2024
- Member of the Duke Cancer Institute, Duke Cancer Institute 2008
Areas of Expertise
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
In the News
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Clinical Focus and Research
My research focuses on new therapies for cancer and non-invasive tests to determine which therapy will help patients best. It is my hope that these technologies will deliver meaningful benefit to patients, reduce side effects and transform the future of cancer care.
-
MOUNTAINEER-03 (Colorectal Cancer)IRB# PRO00110153 , NCT# NCT05253651
-
ABBV-400 in Select Advanced Solid Tumor IndicationsIRB# PRO00113960 , NCT# NCT06084481
-
Study drug RO7589831 for MSI/dMMR solid tumors (BP44474)IRB# PRO00113812 , NCT# NCT06004245
-
Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)IRB# PRO00114908 , NCT# NCT06227377
-
Perioperative dostarlimab vs standard of care for resectable colon cancer (219606) (AZUR)IRB# PRO00113870 , NCT# NCT05855200
-
Amgen2021: Advanced Solid Tumors with KRAS p.G12C MutationIRB# PRO00114638 , NCT# NCT06252649
-
APL-5125 (Gastrointestinal Cancers)IRB# PRO00115529 , NCT# NCT06399757
-
EAY191 (ComboMATCH)IRB# PRO00113715 , NCT# NCT05564377
-
Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)IRB# PRO00114818 , NCT# NCT06040541
-
RMC-6236 (Unresectable or Metastatic Colorectal Cancer or Pancreatic Cancer)IRB# PRO00115657 , NCT# NCT06445062
-
RMC-6236 + cetuximab for colorectal or pancreatic cancer (RMC-GI-102_B)IRB# PRO00115669 , NCT# NCT06445062
-
RMC-6236 + gemcitabine and nab-paclitaxel for pancreatic cancer (RMC-GI-102_C)IRB# PRO00115670 , NCT# NCT06445062
-
Study drug QTX3046 for KRAS G12D mutated advanced solid tumorsIRB# PRO00116299 , NCT# NCT06428500
-
ABBV-400 + fluororuracil, folinic acid, and bevacizumab for colorectal cancer (M24-311)IRB# PRO00113954 , NCT# NCT06107413
-
LY3962673 for KRAS G12D-mutated solid tumorsIRB# PRO00116471 , NCT# NCT06586515
-
Pan-KRAS Inhibitor LY4066434 +/- SOC drugs in KRAS Mutant Solid Tumors (J5Q-OX-JRDA)IRB# PRO00117213 , NCT# NCT06607185
- Strickler, J. H., and M. S. McKinney. Preface, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00007-1.
- Ginsburg, G. S., H. F. Willard, J. H. Strickler, and M. S. McKinney. Genomic and Precision Medicine: Oncology, Third Edition, 2022. https://doi.org/10.1016/C2015-0-06901-5.
- Sharib, Jeremy, Kristen E. Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew, Sabran Masoud, Isabel DeLaura, et al. “Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.” Ann Surg Oncol 32, no. 4 (April 2025): 2456–66. https://doi.org/10.1245/s10434-024-16799-0.
- Liu, Annie, Melissa Lowe, Donna Niedzwiecki, Kristen E. Rhodin, Jeremy Sharib, Benjamin Wildman-Tobriner, Terence Z. Wong, et al. “ASO Visual Abstract: Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding Hai Program.” Ann Surg Oncol 32, no. 4 (April 2025): 2508–9. https://doi.org/10.1245/s10434-024-16611-z.
- Inoue, Kanae, Yoshiaki Nakamura, Bennett Caughey, Binbin Zheng-Lin, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, et al. “Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer.” JCO Precis Oncol 9 (April 2025): e2400718. https://doi.org/10.1200/PO-24-00718.
- McKinney, M. S., and J. H. Strickler. “Introduction and overview of cancer precision medicine.” In Genomic and Precision Medicine: Oncology, Third Edition, 1–11, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00008-3.
- Mettu, Niharika B., and John H. Strickler. “How I Treat Metastatic Colorectal Cancer With Emerging Therapeutic Strategies.” In HANDBOOK OF GASTROINTESTINAL CANCERS: EVIDENCE-BASED TREATMENT AND MULTIDISCIPLINARY PATIENT CARE, 122–31, 2020.
- Liu, Annie, Melissa Lowe, Donna Niedzwiecki, Kristen E. Rhodin, Jeremy Sharib, Benjamin Wildman-Tobriner, Terence Z. Wong, et al. “Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.” In Ann Surg Oncol, 32:1033–42, 2025. https://doi.org/10.1245/s10434-024-16488-y.
- Masuishi, T., J. H. Strickler, J. -. P. Machiels, D. S. Hong, R. Greil, E. Chan, J. Hippenmeyer, et al. “92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort.” In Annals of Oncology, 34:S1505–S1505. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.10.227.
- Strickler, J. H., D. R. Camidge, Y. Kuboki, N. Yamamoto, D. Sommerhalder, A. Vasilopoulos, R. R. Li, et al. “691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors.” In Annals of Oncology, 34:S482–S482. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1877.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- AbbVie, Inc.
- Amgen, Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Bayer
- BeiGene
- Bristol-Myers Squibb (BMS)
- Cytovation
- Daiichi Sankyo Co., Ltd
- Eli Lilly & Co.
- GE Healthcare
- Genentech, Inc (Roche Holding)
- GlaxoSmithKline
- Incyte
- Ipsen
- Jazz Pharmaceuticals
- Johnson and Johnson
- Leap Therapeutics
- Merck Sharp & Dohme Inc., One Merck Drive, Whitehouse Station, NJ 08889-0100.
- Natera
- Pfizer Inc.
- Quanta Therapeutics
- Regeneron Pharmaceuticals
- Sanofi
- Taiho
- Takeda Oncology
- Triumvira Immunologics
- Xilio Therapeutics